GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
News Medical on MSN13h
Study shows RSV’s severe impact on US adults, urging more testing and vaccinationRSV hospitalizations in US adults reached high levels pre-vaccine, especially impacting those 75 and older, underscoring the ...
Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for the Pfizer vaccine, Payne and colleagues reported. Vaccine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback